-
Breast
-
Lung
-
Colorectal
-
Ovarian
-
Hematologic
-
Gastric
-
Solid tumor

:Orphan drug designation (designated in at least one country/region among JP, US)

:Breakthrough Therapy Designation (US)

:Project in oncology that has been submitted for approval in some countries/regions based on the results of Phase2 trials
AGA: actionable genomic alterations,
BC: breast cancer, BTC: biliary tract cancer, CPS: combined positive score, CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, HBL: hepatoblastoma, HCC: hepatocellular carcinoma, ICI: immune checkpoint inhibitor, NSCLC: non-small cell lung cancer, PBC: platinum-based chemotherapy, r/r: relapse or refractory, RMS: rhabdomyosarcoma, SCLC: small cell lung cancer, TBA: to be announced, THP: taxane (paclitaxel or docetaxel) + trastuzumab + pertuzumab, TNBC: triple negative breast cancer, TPS: tumore proportion score